iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://pubmed.ncbi.nlm.nih.gov/36382258/
Multiple sclerosis and computational biology (Review) - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 18;17(6):96.
doi: 10.3892/br.2022.1579. eCollection 2022 Dec.

Multiple sclerosis and computational biology (Review)

Io Diakou  1 , Eleni Papakonstantinou  1 , Louis Papageorgiou  1 , Katerina Pierouli  1 , Konstantina Dragoumani  1 , Demetrios A Spandidos  2 , Flora Bacopoulou  3 , George P Chrousos  3 , Georges Ν Goulielmos  4 , Elias Eliopoulos  1 , Dimitrios Vlachakis  1   3   5
Affiliations
Review

Multiple sclerosis and computational biology (Review)

Io Diakou et al. Biomed Rep. .

Abstract

Multiple sclerosis (MS) is an autoimmune neurodegenerative disease whose prevalence has increased worldwide. The resultant symptoms may be debilitating and can substantially reduce the of patients. Computational biology, which involves the use of computational tools to answer biomedical questions, may provide the basis for novel healthcare approaches in the context of MS. The rapid accumulation of health data, and the ever-increasing computational power and evolving technology have helped to modernize and refine MS research. From the discovery of novel biomarkers to the optimization of treatment and a number of quality-of-life enhancements for patients, computational biology methods and tools are shaping the field of MS diagnosis, management and treatment. The final goal in such a complex disease would be personalized medicine, i.e., providing healthcare services that are tailored to the individual patient, in accordance to the particular biology of their disease and the environmental factors to which they are subjected. The present review article summarizes the current knowledge on MS, modern computational biology and the impact of modern computational approaches of MS.

Keywords: artificial intelligence; bioinformatics; computational biology; multiple sclerosis; personalized medicine.

PubMed Disclaimer

Conflict of interest statement

DAS is the Editor-in-Chief for the journal, but had no personal involvement in the reviewing process, or any influence in terms of adjudicating on the final decision, for this article. The other authors declare that they have no competing interests.

Similar articles

See all similar articles

Cited by

References

    1. Huang WJ, Chen WW, Zhang X. Multiple sclerosis: Pathology, diagnosis and treatments. Exp Ther Med. 2017;13:3163–3166. doi: 10.3892/etm.2017.4410. - DOI - PMC - PubMed
    1. A systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019;18:269–285. GBD 2016 Multiple Sclerosis Collaborators: Global, regional, and national burden of multiple sclerosis 1990-2016. - PMC - PubMed
    1. Cruz-Orengo L, Daniels BP, Dorsey D, Basak SA, Grajales-Reyes JG, McCandless EE, Piccio L, Schmidt RE, Cross AH, Crosby SD, Klein RS. Enhanced sphingosine-1-phosphate receptor 2 expression underlies female CNS autoimmunity susceptibility. J Clin Invest. 2014;124:2571–2584. doi: 10.1172/JCI73408. - DOI - PMC - PubMed
    1. Berger B, Daniels NM, Yu YW. Computational biology in the 21st century: Scaling with compressive algorithms. Commun ACM. 2016;59:72–80. doi: 10.1145/2957324. - DOI - PMC - PubMed
    1. Wang MD. In the spotlight: Bioinformatics, computational biology and systems biology. IEEE Rev Biomed Eng. 2011;4:3–5. doi: 10.1109/RBME.2011.2177935. - DOI - PMC - PubMed

Grants and funding

Funding: The authors would like to acknowledge funding from the following organizations: i) AdjustEBOVGP-Dx (RIA2018EF-2081): Biochemical Adjustments of native EBOV Glycoprotein in Patient Sample to Unmask target Epitopes for Rapid Diagnostic Testing. A European and Developing Countries Clinical Trials Partnership (EDCTP2) under the Horizon 2020 ‘Research and Innovation Actions’ DESCA; and ii) ‘MilkSafe: A novel pipeline to enrich formula milk using omics technologies’, a research co-financed by the European Regional Development Fund of the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH-CREATE-INNOVATE (project code: T2EDK-02222).